- What are cytokines?
- Early experiments
- Human cytokines in the 1980s
- Identification of TNFalpha at protein and genomic level
- TNFalpha and anti-TNFalpha antibodies
- Rheumatoid arthritis (RA): burden of disease
- Pathology of RA
- IL-1 and TNFalpha
- Cytokine cascade in RA
- A molecular hypothesis
- First anti-TNF (cA2/infliximab) in clinical trials in RA
- How does anti-TNF work?
- Why is cellularity reduced?
- Anti-TNF therapy inhibits cartilage and especially bone destruction
- Infliximab regulates altered T and B cell immunity
- Biological effects of Infliximab
- Anti-TNF biologicals in the lab
- Efficacy in randomized clinical trials
- Effective anti-TNF therapy demonstrates shared TNF-pathways in other diseases
- Adverse events and safety issues
- Limitations of anti-TNF therapy
- After TNF: what are we looking for?
Maini, R. (2009, May 31). From bench to bedside: evolution of anti-TNFalpha therapy in rheumatoid arthritis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks
. Retrieved June 5, 2023, from https://hstalks.com/bs/1314/
Export Citation (RIS)
Published on May 31, 2009
- Prof. Sir Ravinder Maini has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.